title: Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia.
abstract: BACKGROUND
  Controversial data on the expression pattern of microRNA-370 (miR-370) in acute myeloid leukemia (AML) were previously reported.
  
  
  OBJECTIVE
  To clarify the expression pattern of miR-370 and its clinical implications in pediatric AML patients.
  
  
  METHODS
  Real-time quantitative PCR was performed to detect the expression of miR-370 in both bone marrow mononuclear cells and sera obtained from pediatric AML patients and healthy controls.
  
  
  RESULTS
  Compared with healthy controls, the expression levels of miR-370 in the bone marrow and sera of pediatric AML patients were both decreased significantly (both P=0.001). Importantly, serum miR-370 level could efficiently screen pediatric AML patients from healthy controls (Area under receiver operating characteristic curve, AUC =0.993). Then, low serum miR-370 level was significantly associated with French-American-British (FAB) classification subtype M7 subtype (P=0.02) and unfavorable karyotype (P=0.01). Moreover, pediatric AML patients with low serum miR-370 level had shorter relapse-free and overall survivals than those with high serum miR-370 level (both P=0.001). Multivariate analysis further identified serum miR-370 level as an independent prognostic factor for both relapse-free and overall survivals. Interestingly, the prognostic relevance of serum miR-370 level was more obvious in the subgroup of patients with intermediate-risk cytogenetics.
  
  
  CONCLUSIONS
  MiR-370 expression may be markedly and consistently decreased in pediatric AML patients and in turn contributes to aggressive progression of this malignancy. Serum miR-370 may serve as a potential non-invasive diagnostic/prognostic marker for pediatric AML patients.
authors.affiliation: Department of Pediatric Intensive Care Units, Huai'an Maternity and Child Health Hospital of Yangzhou University Huai'an 223002, Jiangsu Province, P.R. China.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Lin
authors.affiliation: Department of Pediatrics, Huai'an Hospital Affiliated of Xuzhou Medical College and Huai'an Second People's Hospital 62 Huaihai Road South, Huai'an 223002, P.R. China.
authors.forename: Zhengyan
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Child Health Care, Huai'an Maternity and Child Health Hospital of Yangzhou University Huai'an 223002, P.R. China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University 6 Beijing Road West, Huai'an, Jiangsu 223300, P.R. China.
authors.forename: Weijing
authors.initials: W
authors.lastname: Feng
mesh_terms: D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis* / Q000235:genetics; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D011379:Prognosis; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; C526503:MIRN370 microRNA, human; D035683:MicroRNAs
keywords: Pediatric acute myeloid leukemia; microRNA-370; prognosis; real-time quantitative PCR; serum
references.citation: Semin Oncol. 2011 Apr;38(2):215-24
references.pmid: 21421111
references.citation: Genome Res. 2004 Sep;14(9):1741-8
references.pmid: 15310658
references.citation: Hepatology. 2013 Dec;58(6):1977-91
references.pmid: 23728999
references.citation: Br J Cancer. 2011 Mar 1;104(5):808-18
references.pmid: 21304530
references.citation: J Lab Autom. 2015 Oct;20(5):574-88
references.pmid: 25524488
references.citation: Mol Cancer. 2012;11:56
references.pmid: 22900969
references.citation: EMBO Mol Med. 2012 Mar;4(3):143-59
references.pmid: 22351564
references.citation: Biomed Pharmacother. 2013 Jul;67(6):521-6
references.pmid: 23721824
references.citation: Curr Hematol Malig Rep. 2014 Jun;9(2):93-9
references.pmid: 24609756
references.citation: Drug Discov Today. 2013 Mar;18(5-6):282-9
references.pmid: 23064097
references.citation: Annu Rev Pharmacol Toxicol. 2011;51:25-43
references.pmid: 20809797
references.citation: PLoS One. 2012;7(9):e45825
references.pmid: 23029264
references.citation: Genes Chromosomes Cancer. 2010 Mar;49(3):193-203
references.pmid: 20013895
references.citation: Biol Cell. 2008 Mar;100(3):149-66
references.pmid: 18271756
references.citation: Genome Med. 2013 Dec 30;5(12):111
references.pmid: 24373327
references.citation: PLoS One. 2012;7(10):e45606
references.pmid: 23110045
references.citation: Front Med China. 2010 Dec;4(4):356-62
references.pmid: 21125345
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:47-55
references.pmid: 21239770
references.citation: PLoS One. 2012;7(10):e47717
references.pmid: 23077663
references.citation: Cancer Lett. 2014 Oct 28;353(2):201-10
references.pmid: 25063739
references.citation: PLoS One. 2013;8(2):e56718
references.pmid: 23437222
references.citation: Biomed Pharmacother. 2014 Mar;68(2):149-54
references.pmid: 24055400
references.citation: Nat Rev Drug Discov. 2010 Oct;9(10):775-89
references.pmid: 20885409
references.citation: Am J Hematol. 2013 Apr;88(4):318-27
references.pmid: 23526416
references.citation: Pharmacol Res. 2013 Sep;75:3-14
references.pmid: 23537752